CN105792845A - 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌 - Google Patents

使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌 Download PDF

Info

Publication number
CN105792845A
CN105792845A CN201480053041.5A CN201480053041A CN105792845A CN 105792845 A CN105792845 A CN 105792845A CN 201480053041 A CN201480053041 A CN 201480053041A CN 105792845 A CN105792845 A CN 105792845A
Authority
CN
China
Prior art keywords
combination
hypoxia
alkyl
paclitaxel
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480053041.5A
Other languages
English (en)
Chinese (zh)
Inventor
C·P·哈特
J·D·孙
B·A·埃伦巴斯
A·瓜尔贝托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Molecular Templates Inc
Original Assignee
Merck Patent GmbH
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH, Threshold Pharmaceuticals Inc filed Critical Merck Patent GmbH
Publication of CN105792845A publication Critical patent/CN105792845A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480053041.5A 2013-07-26 2014-07-23 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌 Pending CN105792845A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361859152P 2013-07-26 2013-07-26
US61/859,152 2013-07-26
US201361887873P 2013-10-07 2013-10-07
US61/887,873 2013-10-07
US201461994295P 2014-05-16 2014-05-16
US61/994,295 2014-05-16
PCT/US2014/047885 WO2015013448A1 (en) 2013-07-26 2014-07-23 Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane

Publications (1)

Publication Number Publication Date
CN105792845A true CN105792845A (zh) 2016-07-20

Family

ID=51299053

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480053041.5A Pending CN105792845A (zh) 2013-07-26 2014-07-23 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌

Country Status (5)

Country Link
US (1) US20160158253A1 (enExample)
EP (1) EP3024490A1 (enExample)
JP (1) JP2016528217A (enExample)
CN (1) CN105792845A (enExample)
WO (1) WO2015013448A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018028494A1 (zh) * 2016-08-09 2018-02-15 江苏千之康生物医药科技有限公司 吉西他滨ProTide乏氧活化前药及其应用
CN110168658A (zh) * 2016-10-05 2019-08-23 皇家飞利浦有限公司 患者监测系统和方法
WO2020007106A1 (zh) * 2018-07-05 2020-01-09 深圳艾欣达伟医药科技有限公司 埃夫索胺的抗癌医药用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
EP3768172B1 (en) * 2018-03-23 2024-02-28 Adenocyte Ltd. Method to induce exfoliation of cells and/or tissue fragments for enhanced cytopathologic cell collection
US20240366640A1 (en) 2021-08-27 2024-11-07 Ascentawits Pharmaceuticals, Ltd. Lyophilized formulation solution and lyophilized formulation, and method and use thereof
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
WO2023174319A1 (zh) 2022-03-15 2023-09-21 深圳艾欣达伟医药科技有限公司 治疗brca突变癌症患者的方法
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
EP4529926A1 (en) 2022-05-23 2025-04-02 Ascentawits Pharmaceuticals, Ltd. Method for treating cancer by combining alkylating agent prodrug and cell cycle inhibitor
WO2024061346A1 (zh) 2022-09-22 2024-03-28 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808614A (en) * 1983-03-10 1989-02-28 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1993021173A1 (en) * 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives
WO2012135757A2 (en) * 2011-04-01 2012-10-04 Threshold Pharmaceuticals, Inc. Methods for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
NZ521851A (en) 2002-10-08 2005-02-25 Auckland Uniservices Ltd Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
WO2005042471A1 (en) 2003-10-31 2005-05-12 Auckland Uniservices Limited Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
CA2613312C (en) 2005-06-29 2014-10-14 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
CA2624707A1 (en) 2005-10-03 2007-04-12 Genetix Pharmaceuticals, Inc. Method for selectively depleting hypoxic cells
US8552048B2 (en) 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
EP2350664B1 (en) * 2008-10-21 2021-05-19 ImmunoGenesis, Inc. Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed
RU2576609C2 (ru) * 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
MX2012014416A (es) 2010-06-28 2013-02-27 Threshold Pharmaceuticals Inc Tratamiento de cancer de sangre.
EP3311835B1 (en) 2010-07-12 2021-03-24 Threshold Pharmaceuticals Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
WO2012142520A2 (en) 2011-04-15 2012-10-18 Threshold Pharmaceuticals, Inc. Unit dose form for oral administration
US9254299B2 (en) 2011-12-22 2016-02-09 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
EP2793899A4 (en) 2011-12-22 2015-06-17 Threshold Pharmaceuticals Inc HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT
JP6360438B2 (ja) 2012-02-21 2018-07-18 モレキュラー テンプレーツ，インコーポレイテッド 癌の治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808614A (en) * 1983-03-10 1989-02-28 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1993021173A1 (en) * 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives
WO2012135757A2 (en) * 2011-04-01 2012-10-04 Threshold Pharmaceuticals, Inc. Methods for treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DONG-SHENG ZHANG等: "Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer", 《CANCER CHEMOTHERAPY AND PHARMACOLOGY》 *
QIAN LIU等人: "TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules", 《CANCER CHEMOTHERAPY AND PHARMACOLOGY》 *
孙慧君等主编: "《药理学》", 31 July 2012, 清华大学出版社 *
徐志巧等主编: "《新编实用肿瘤临床药物手册》", 30 June 2013, 中国医药科技出版社 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018028494A1 (zh) * 2016-08-09 2018-02-15 江苏千之康生物医药科技有限公司 吉西他滨ProTide乏氧活化前药及其应用
US10709725B2 (en) 2016-08-09 2020-07-14 Jiangsu Qianzhikang Biological Medicine Science And Technology Co., Ltd Gemcitabine ProTide hypoxia-activated prodrug and application thereof
CN110168658A (zh) * 2016-10-05 2019-08-23 皇家飞利浦有限公司 患者监测系统和方法
CN110168658B (zh) * 2016-10-05 2024-04-02 皇家飞利浦有限公司 患者监测系统和方法
WO2020007106A1 (zh) * 2018-07-05 2020-01-09 深圳艾欣达伟医药科技有限公司 埃夫索胺的抗癌医药用途

Also Published As

Publication number Publication date
US20160158253A1 (en) 2016-06-09
EP3024490A1 (en) 2016-06-01
JP2016528217A (ja) 2016-09-15
WO2015013448A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CN105792845A (zh) 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
RU2576609C2 (ru) Способы лечение рака поджелудочной железы
JP6342918B2 (ja) 膵臓がんの処置方法
USRE45105E1 (en) Method of treating cancer by co-administration of anticancer agents
KR101712231B1 (ko) 카바지탁셀의 신규한 항종양 용도
US20160074390A1 (en) Human dosing of phosphatase inhibitor
KR20150126038A (ko) 폐암의 치료 방법
TW202027727A (zh) 使用包含微脂體伊立替康（ｉｒｉｎｏｔｅｃａｎ）的組合療法治療胰臟癌的方法
EP2817011B1 (en) Treatment of cancer
JP7113619B2 (ja) リポソーマルイリノテカンによる乳がんの治療
Paudel et al. Targeting lung cancer using advanced drug delivery systems
Kollmannsberger et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
Di Lauro et al. Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer
Huisman et al. A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients
HK40009403A (en) Methods of treating pancreatic cancer
WO2020243745A1 (en) Methods and uses for treating cancer
Standard et al. Pr PACLITAXEL FOR INJECTION
Kerklaan et al. SQ109 showed activity against both drug susceptible and multi-drug-resistant tuberculosis bacteria, including extensively drug-resistant tuberculosis strains Menu
HK1204956B (en) Treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160720

WD01 Invention patent application deemed withdrawn after publication